PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

INITIAL PSA SERUM LEVEL AND ITS RELATION TO PROSTATE CANCER PROGRESSION IN MEN TREATED HORMONALLY
Article published in Urologia Polska 2000/53/3.

authors

Romuald Zdrojowy, Jerzy Lorenz, Janusz Dembowski, Anna Kołodziej
Katedra i Klinika Urologii Akademii Medycznej we Wrocławiu
Kierownik Kliniki: prof. dr hab. med. J. Lorenz

keywords

prostate cancer maximal androgen blockade PSA disease progression

summary

Objectives. Androgen deprivation is the common treatment method of men
with locally advanced prostate cancer. Nowadays there no data what kind of
treatment - immediate or deferred - is more effective.
Aim of the study. The aim was Comparing prostate cancer progression in
men with locally advanced disease with relation to initial serum PSA level.
So the relations between serum PSA level and biochemical progression
fre±uency and time to any progression was to be examined.
Material and methods. 112 men with locally advanced prostate cancer
T3NxM0
years. The men were treated by maximal androgen blockade. The main
oncological effectiveness criterion was the presence or abscence of the disease
progression. The prostate cancer progression was defined as biochemical,
local or general progression. The biochemical progression fre±uency and time
to biochemical, local and general progression were statistically analyzed.
Results. During the time observation biochemical progression was observed
in 99/112 (88.4%) patients; without were 13/112 (11.6%). The was no statistically
significant difference between initial serum PSA level and the biochemical
progression fre±uency (p > 0,05). There were also no correlation between serum
PSA level and time to biochemical, local and general progression.
Conclusion. There was no relation between biochemical progression
frequency and no correlation with time to biochemical, local and general
progression and initial serum PSA level in men with locally advanced prostate
cancer treated by maximal androgen blockade.

references

  1. [1] Adolf sson, J., Carstensen, J., Lowhagen, T.: Deferred treatment in clinically
  2. localized prostatic carcinoma. Br. J. Urol. 1992, 69,183-188.
  3. [2] Adolf sson, J.: Deferred treatment of low grade stage T3 prostate cancer without
  4. distant metastases. J. Urol. 1993,149,326-329.
  5. [3] Altwein, J. E.: Therapeutic options in locally defined or advanced prostate cancer.
  6. Eur. Urol. 1999, 35, Suppl. 1, 9-12.
  7. [4] Anderson, J. B.: Early versus deferred hormone therapy. Eur. Urol. 1999, 36,
  8. Suppl. 2, 9-14.
  9. [5] Byar, D. P., Corle, D. K.: Hormone therapy for prostate cancer: results of the
  10. Veterans Administration Cooperative Urological Research Group Studies. NCI Mono-
  11. graph 1988, 7,165-170.
  12. [6] Fleshner, N. E., Trachtenberg, J.: Postepy i kontrowersje dotyczqce blokady
  13. androgenowej u chorych z zaawansowanym rakiem stercza. AUA Update Series
  14. 1998, 16, 74-79.
  15. [7] Huland, H., Graefen, M., Hammerer, P., Noldus, J., Haese, A., Fernan-
  16. dez, S., Huland, E.: Multivariate analysis ofpreoperative parameters for predic-
  17. tion of early PSA relapse after radical prostatectomy (RP). J. Urol. 1999,161, suppl.
  18. 4, 334.
  19. [8] Kleer, E., Oesterling, J. E.: PSA and staging of localized prostate cancer. Urol.
  20. Clin. N. Am. 1993, 20, 695-704.
  21. [9] Newling, D. W.: Treating clinically advanced, localized prostate cancer. Clin. Care
  22. Prostatic Disease 1996, 4,11-16.
  23. [10] Oesterling, J. E., Suman, V. J., Zincke, H., Bostwick, D. G.: PSA -detected
  24. (clinical stage Tlc or BJ prostate cancer: pathologically significant tumors. Urol.
  25. Clin. N. Am. 1993, 20, 687-693.
  26. [11] Partin, W., Pound, C. R., Eisenberger, M. A., Chan, D. W., Pearson, J. D.,
  27. Walsh, P. C: Prostate-specific antigen doubling time (PSADT), Gleason score and
  28. the time to PSA recurrence following radical prostatectomy predicts time to distant
  29. progression. J. Urol. 1999,161, Suppl. 4,175.
  30. [12] Schroder, F. H.: Leczenie hormonalne raka gruczolu krokowego - wspolczesne
  31. osiqgniecia i przyszlosc:. Czesc 1 maksymalna blokada androgenowa, leczenie wcz-
  32. esne versus, leczenie opoznione; dzialania niepozqdane. Eur. Urol. Update Series
  33. 1999, 1, 5-15.
  34. [13] Sherrill, L. A., Iocca, A. J., Blute, M. L., Bostwick, D. G., Zincke, H.:
  35. Clinical The prostate cancer treated by radical prostatectomy: outcome according to
  36. preoperative PSA and clinical grade in the PSA era. J. Urol. 1999,161, Suppl. 155.
  37. [14] The Medical Research Council Prostate Cancer Working Party Investi-
  38. gators Group: Immediate versus deferred treatment for advenced prostatic cancer:
  39. initial results of the Medical Research Cuncil Trial Br. J. Urol. 1997, 79, 235-246.
  40. [15] Zdrojowy, R.: Historia naturalna raka stercza. Choroby gruczołu krokowego. Wyd.
  41. Lek. PZWL, Warszawa 1997, 234-242.